A new chemical probe for quantitative proteomic profiling of fibroblast growth factor receptor and its inhibitors

Journal of Proteomics

Volumn 96, Issue , 2014, Pages 44-55

  Ku, Xin ^a   Heinzlmeir, Stephanie ^a   Liu, Xiaofeng ^c   Médard, Guillaume ^a   Kuster, Bernhard ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Munich Center for Integrated Protein Science   (Germany)

^c EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Chemical proteomics; FGFR; Kinobeads; LC MS MS

Indexed keywords

DOVITINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; ORANTINIB; PHOSPHOTRANSFERASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN RET; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL LYSATE; CHEMICAL PROCEDURES; CONTROLLED STUDY; DRUG BINDING; DRUG SELECTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR PROBE; PLACENTA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEOMICS; QUANTITATIVE ANALYSIS; SYNTHESIS;

CHEMICAL PROTEOMICS; FGFR; KINOBEADS; LC-MS/MS;

FEMALE; GENE EXPRESSION PROFILING; HUMANS; K562 CELLS; NEOPLASM PROTEINS; NEOPLASMS; PLACENTA; PREGNANCY; PREGNANCY PROTEINS; PROTEOMICS; RECEPTORS, FIBROBLAST GROWTH FACTOR;

EID: 84888093389     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.10.031     Document Type: Article

References (40)

1. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
2. Kruse U., Bantscheff M., Drewes G., Hopf C. Chemical and pathway proteomics: powerful tools for oncology drug discovery and personalized health care. Mol Cell Proteomics 2008, 7:1887-1901.
3. Wilhelm S.M., Adnane L., Newell P., Villanueva A., Llovet J.M., Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008, 7:3129-3140.
4. Knapp S., Arruda P., Blagg J., Burley S., Drewry D.H., Edwards A., et al. A public-private partnership to unlock the untargeted kinome. Nat Chem Biol 2013, 9:3-6.
5. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008, 26:127-132.
6. Schirle M., Bantscheff M., Kuster B. Mass spectrometry-based proteomics in preclinical drug discovery. Chem Biol 2012, 19:72-84.
7. Zinn N., Hopf C., Drewes G., Bantscheff M. Mass spectrometry approaches to monitor protein-drug interactions. Methods 2012, 57:430-440.
8. Bantscheff M., Drewes G. Chemoproteomic approaches to drug target identification and drug profiling. Bioorg Med Chem 2012, 20:1973-1978.
9. Mallick P., Kuster B. Proteomics: a pragmatic perspective. Nat Biotechnol 2010, 28:695-709.
10. Bantscheff M., Schirle M., Sweetman G., Rick J., Kuster B. Quantitative mass spectrometry in proteomics: a critical review. Anal Bioanal Chem 2007, 389:1017-1031.
11. Bantscheff M., Kuster B. Quantitative mass spectrometry in proteomics. Anal Bioanal Chem 2012, 404:937-938.
12. Schirle M., Petrella E.C., Brittain S.M., Schwalb D., Harrington E., Cornella-Taracido I., et al. Kinase inhibitor profiling using chemoproteomics. Methods Mol Biol 2012, 795:161-177.
13. Godl K., Wissing J., Kurtenbach A., Habenberger P., Blencke S., Gutbrod H., et al. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci U S A 2003, 100:15434-15439.
14. Graves P.R., Kwiek J.J., Fadden P., Ray R., Hardeman K., Coley A.M., et al. Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol Pharmacol 2002, 62:1364-1372.
15. Patricelli M.P., Szardenings A.K., Liyanage M., Nomanbhoy T.K., Wu M., Weissig H., et al. Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry 2007, 46:350-358.
16. Bantscheff M., Eberhard D., Abraham Y., Bastuck S., Boesche M., Hobson S., et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007, 25:1035-1044.
17. Li J., Rix U., Fang B., Bai Y., Edwards A., Colinge J., et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 2010, 6:291-299.
18. Wu Z., Doondeea J.B., Gholami A.M., Janning M.C., Lemeer S., Kramer K., et al. Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer. Mol Cell Proteomics 2011, 10(M111):011635.
19. Lemeer S., Zorgiebel C., Ruprecht B., Kohl K., Kuster B. Comparing immobilized kinase inhibitors and covalent ATP probes for proteomic profiling of kinase expression and drug selectivity. J Proteome Res 2013, 12(4):1723-1731.
20. Sharma K., Weber C., Bairlein M., Greff Z., Keri G., Cox J., et al. Proteomics strategy for quantitative protein interaction profiling in cell extracts. Nat Methods 2009, 6:741-744.
21. Pachl F., Plattner P., Ruprecht B., Médard G., Sewald N., Kuster B. Characterization of a chemical affinity probe targeting AKT kinases. J Proteome Res 2013, 12(8):3792-3800.
22. Zhang L., Holmes I.P., Hochgrafe F., Walker S.R., Ali N.A., Humphrey E.S., et al. Characterization of the novel broad-spectrum kinase inhibitor CTx-0294885 as an affinity reagent for mass spectrometry-based kinome profiling. J Proteome Res 2013, 12:3104-3116.
23. Brooks A.N., Kilgour E., Smith P.D. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 2012, 18:1855-1862.
24. Ahmad I., Iwata T., Leung H.Y. Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta 1823, 2012:850-860.
25. Pachl F., Plattner P., Ruprecht B., Médard G., Sewald N., Kuster B. Characterization of a chemical affinity probe targeting AKT kinases. J Proteome Res 2013, 12:3792-3800.
26. Wu Z., Moghaddas Gholami A., Kuster B. Systematic identification of the HSP90 candidate regulated proteome. Mol Cell Proteomics 2012, 11(M111):016675.
27. Olsen J.V., de Godoy L.M., Li G., Macek B., Mortensen P., Pesch R., et al. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Mol Cell Proteomics 2005, 4:2010-2021.
28. Mohammadi M., Froum S., Hamby J.M., Schroeder M.C., Panek R.L., Lu G.H., et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 1998, 17:5896-5904.
29. Sharpe R., Pearson A., Herrera-Abreu M.T., Johnson D., Mackay A., Welti J.C., et al. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res 2011, 17:5275-5286.
30. Pardo O.E., Latigo J., Jeffery R.E., Nye E., Poulsom R., Spencer-Dene B., et al. The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res 2009, 69:8645-8651.
31. Barvian M., Boschelli D.H., Cossrow J., Dobrusin E., Fattaey A., Fritsch A., et al. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem 2000, 43:4606-4616.
32. Anastassiadis T., Deacon S.W., Devarajan K., Ma H., Peterson J.R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 2011, 29:1039-1045.
33. Godl K., Gruss O.J., Eickhoff J., Wissing J., Blencke S., Weber M., et al. Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. Cancer Res 2005, 65:6919-6926.
34. Sun L., Tran N., Liang C., Tang F., Rice A., Schreck R., et al. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J Med Chem 1999, 42:5120-5130.
35. Ahmed S.I., Thomas A.L., Steward W.P. Vascular endothelial growth factor (VEGF) inhibition by small molecules. J Chemother 2004, 16(Suppl. 4):59-63.
36. Kim D.W., Jo Y.S., Jung H.S., Chung H.K., Song J.H., Park K.C., et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006, 91:4070-4076.
37. Sawamiphak S., Seidel S., Essmann C.L., Wilkinson G.A., Pitulescu M.E., Acker T., et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 2010, 465:487-491.
38. Wang Y., Nakayama M., Pitulescu M.E., Schmidt T.S., Bochenek M.L., Sakakibara A., et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 2010, 465:483-486.
39. Goncalves A., Burckstummer T., Dixit E., Scheicher R., Gorna M.W., Karayel E., et al. Functional dissection of the TBK1 molecular network. PLoS One 2011, 6:e23971.
40. Chariot A., Leonardi A., Muller J., Bonif M., Brown K., Siebenlist U. Association of the adaptor TANK with the I kappa B kinase (IKK) regulator NEMO connects IKK complexes with IKK epsilon and TBK1 kinases. J Biol Chem 2002, 277:37029-37036.